Advaxis seeks ADXS-HPV Orphan Drug Designation for treatment of HPV-associated anal cancer Advaxis.

The incidence of anal tumor has increased more than twofold from 1975-2009 and is rising,’ commented Dr. Robert Petit, Chief Scientific Officer of Advaxis. We wish that ADXS-HPV will improve survival for individuals with HPV-associated anal cancer.S.9 million regulatory program filing fee,’ commented Thomas A. Moore, Chairman and Chief Executive Officer of Advaxis. ‘We are looking towards initial data from our Brown University Study in anal cancer that is currently underway.’..Kaiser Family Foundation. Copyright 2009 Advisory Board Organization and Kaiser Family Basis. All rights reserved.

A guide to peripheral oedema Peripheral oedema is a nonspecific symptom with a wide range of potential causes. A systematic time-efficient review of the patient shall assist in differentiating the benign from the much more serious causes, guide initial investigations and determine who could be managed in the grouped community and who requires specialist referral or hospitalisation. The differential diagnosis of peripheral oedema is certainly wide, needing a systematic approach intended for management and diagnosis.